8-Quinolinol, 7-(1,1-dimethylethyl)- | 52794-00-0

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 喹啉及其衍生物
• 英文名称: 8-Quinolinol, 7-(1,1-dimethylethyl)-
• 英文别名: 7-tert-butylquinolin-8-ol
• CAS: 52794-00-0
• 化学式: C₁₃H₁₅NO
• 分子量: 201.26
• InChiKey: PANCGJXKJLJQND-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.5
• 重原子数：
  15
• 可旋转键数：
  1
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.31
• 拓扑面积：
  33.1
• 氢给体数：
  1
• 氢受体数：
  2

文献信息

• Imine Compound
  申请人：Saito Shiuji

  公开号：US20080312435A1

  公开（公告）日：2008-12-18

  An imine compound represented by the formula: wherein A represents a heterocyclic group; R 1 , R 2 , an R 3 each represent a hydrogen atom, a halogen atom, a C 1-10 alkyl group optionally substituted with an aryl group(s) substituted with a halogen atom(s), a C 3-10 cycloalkyl group, a C 1-6 haloalkyl group, a C 1-10 alkoxy group, etc.; R 4 represents an optionally substituted C 1-10 alkyl, C 2-6 alkenyl, or aryl group; R 5 represents a hydrogen atom, a C 1-10 alkoxy group, a C 1-6 haloalkyl group, an optionally substituted C 1-10 alkyl or C 2-6 alkenyl group, an optionally substituted aryl or heterocyclic group, etc.; W represents —CO—, —CO—CO—, —CO—NH—, —CS—NH—, or —SO 2 —, or a cannabinoid-receptor agonist comprising said imine compound as an active ingredient. The imine compound of the present invention has a cannabinoid-receptor agonist effect, and is useful as a therapeutic or prophylactic drug for pains and autoimmune diseases.

  一种以以下式表示的亚胺化合物：其中A代表杂环基团；R1、R2和R3分别表示氢原子、卤素原子、C1-10烷基，该烷基可选地取代有芳基，所述芳基取代有卤素原子，C3-10环烷基，C1-6卤代烷基，C1-10烷氧基等；R4表示可选地取代的C1-10烷基，C2-6烯基或芳基；R5表示氢原子，C1-10烷氧基，C1-6卤代烷基，可选地取代的C1-10烷基或C2-6烯基，可选地取代的芳基或杂环基团等；W表示—CO—，—CO—CO—，—CO—NH—，—CS—NH—或—SO2—，或以该亚胺化合物为活性成分的大麻素受体激动剂。本发明的亚胺化合物具有大麻素受体激动剂作用，可用作治疗或预防疼痛和自身免疫性疾病的药物。
• METHOD FOR PRODUCING FARNESAL USING VANADIUM COMPLEX
  申请人：SAGAMI CHEMICAL RESEARCH INSTITUTE

  公开号：US20150126740A1

  公开（公告）日：2015-05-07

  The present invention provides a method for producing farnesal that is useful as a production intermediate of pharmaceuticals, agricultural chemicals and perfumes. More specifically, the present invention provides a method for producing farnesal (3), comprising reacting (E)-nerolidol (1) with an oxidizing agent in the presence of a vanadium complex of the general formula (2): wherein R 1 to R 7 are the same as defined in the description and claims.

  本发明提供了一种生产法尼醛的方法，该法尼醛可用作制药、农药和香料的生产中间体。更具体地，本发明提供了一种生产法尼醛（3）的方法，包括在钒配合物（2）的存在下，通过将（E）-芳樟醇（1）与氧化剂反应来制备法尼醛，其中配合物的一般式为：其中R1至R7与说明书和权利要求书中定义的相同。
• Metal Complexes
  申请人：MERCK PATENT GMBH

  公开号：US20160211468A1

  公开（公告）日：2016-07-21

  The present invention relates to metal complexes, to compositions and formulations comprising these complexes, and to devices comprising the complexes or compositions.

  本发明涉及金属配合物，涉及包含这些配合物的组成物和配方，以及包含这些配合物或组成物的装置。
• PRMT5 INHIBITORS CONTAINING A DIHYDRO- OR TETRAHYDROISOQUINOLINE AND USES THEREOF
  申请人：EPIZYME, INC.

  公开号：US20150344433A1

  公开（公告）日：2015-12-03

  Described herein are compounds of Formula (A), pharmaceutically acceptable salts thereof, and pharmaceutical compositions thereof. Compounds of the present invention are useful for inhibiting PRMT5 activity. Methods of using the compounds for treating PRMT5-mediated disorders are also described.

  本文描述了公式（A）的化合物，其药学上可接受的盐和药物组合物。本发明的化合物可用于抑制PRMT5活性。还描述了使用这些化合物治疗PRMT5介导的疾病的方法。
• PRMT5 INHIBITORS AND USES THEREOF
  申请人：EPIZYME, INC.

  公开号：US20150361042A1

  公开（公告）日：2015-12-17

  Described herein are compounds of formula (A), pharmaceutically acceptable salts thereof, and pharmaceutical compositions thereof. Compounds of the present invention are useful for inhibiting PRMT5 activity. Methods of using the compounds for treating PRMT5-mediated disorders are also described.

  本文描述了A式化合物及其药学上可接受的盐和制药组合物。本发明的化合物对于抑制PRMT5活性是有用的。本文还描述了使用这些化合物治疗PRMT5介导的疾病的方法。